Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | terminated | Phase 2 | 3 | AIO-Studien-gGmbHOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 7 | SignalRX Pharmaceuticals, Inc.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT02866344 | Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases | terminated | N/A | 1 | Wake Forest University Health SciencesOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 140 | Polaris GroupINDUSTRY | 6 | Apr 25, 2022 | clinicaltrials |
| NCT02704130 | TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma | terminated | N/A | 8 | Wake Forest University Health SciencesOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT03396705 | Liver Regeneration | terminated | — | 2 | University Health Network, TorontoOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | terminated | N/A | 53 | IHU StrasbourgOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03979547 | EXALT: EXercise Attenuates Liver Tumors Trial(EXALT) | terminated | N/A | 3 | Milton S. Hershey Medical CenterOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT04648319 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | terminated | Phase 2 | 1 | American University of Beirut Medical CenterOTHER | 3 | Feb 23, 2022 | clinicaltrials |
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | terminated | Phase 2 | 4 | Aiwu Ruth He, MDOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT04653389 | Perioperative Therapy for Hepatocellular Carcinoma | terminated | Phase 2 | 10 | Zhejiang UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04476329 | Optimization for Regorafenib in HCC(ReDos HCC) | terminated | Phase 2 | 7 | SC Liver Research Consortium, LLCOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer(HiQuality) | terminated | Phase 3 | 235 | Merit Medical Systems, Inc.INDUSTRY | 5 | Nov 30, 2021 | clinicaltrials |
| NCT02304289 | Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma(DESPARTH) | terminated | Phase 1 | 2 | University Hospital, GhentOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT01141478 | Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria(HCC) | terminated | N/A | 8 | Loma Linda UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT01098422 | A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver | terminated | N/A | 10 | Tony Reid, M.D., Ph.D.OTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT03203304 | Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer | terminated | Phase 1 | 14 | University of ChicagoOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT01032850 | Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | terminated | Phase 2 | 15 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02893982 | High Dose Rate Brachyablation of Primary Liver Lesions | terminated | Phase 1 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT02721056 | NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers | terminated | Phase 1 / Phase 2 | 23 | NanobiotixINDUSTRY | 1 | May 10, 2021 | clinicaltrials |
| NCT03608878 | Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype | terminated | Phase 2 | 5 | Chang Gung Memorial HospitalOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT04264754 | Characterization of Methylation Patterns in Hepatocellular Carcinoma | terminated | — | 120 | Nucleix Ltd.INDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT01887717 | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein(YES-P) | terminated | Phase 3 | 36 | Boston Scientific CorporationINDUSTRY | 6 | Apr 21, 2021 | clinicaltrials |
| NCT03516695 | RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry(READ90Y) | terminated | — | 95 | Boston Scientific CorporationINDUSTRY | 2 | Apr 21, 2021 | clinicaltrials |
| NCT03137706 | Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer | terminated | — | 8 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03563274 | QuiremSpheres Observational Study(Hope166) | terminated | — | 20 | Terumo Europe N.V.INDUSTRY | 2 | Mar 29, 2021 | clinicaltrials |
| NCT03303469 | Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging | terminated | Phase 2 | 3 | University of Alabama at BirminghamOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02460991 | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma(SOLACE) | terminated | Phase 3 | 2 | Boston Scientific CorporationINDUSTRY | 1 | Feb 12, 2021 | clinicaltrials |
| NCT03008512 | A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib | terminated | Phase 2 | 5 | Gachon University Gil Medical CenterOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02524119 | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma(LEE001) | terminated | Phase 2 | 5 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02470533 | Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma(TRENDY) | terminated | Phase 2 | 100 | Erasmus Medical CenterOTHER | 3 | Jan 27, 2021 | clinicaltrials |
| NCT03219372 | Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence | terminated | Phase 2 | 1 | Cedars-Sinai Medical CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02992340 | Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC | terminated | Phase 1 / Phase 2 | 204 | ASLAN PharmaceuticalsOTHER | 3 | Jan 14, 2021 | clinicaltrials |
| NCT04702230 | Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization | terminated | — | 32 | University of ZurichOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT00823290 | Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 | 2 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT00503867 | SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | terminated | N/A | 10 | Sirtex MedicalINDUSTRY | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT02966223 | A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver | terminated | N/A | 20 | Indiana UniversityOTHER | 1 | Sep 25, 2020 | clinicaltrials |
| NCT03203837 | Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | terminated | — | 4 | Northwestern UniversityOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03644511 | Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment(SORAGO-HCC) | terminated | — | 3 | BayerINDUSTRY | 1 | Aug 21, 2020 | clinicaltrials |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | terminated | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 23, 2022source: clinicaltrials